IGF-1 Biochemical Testing: Principles, Analytical Methods, and Clinical Applications

IGF-1 biochemical testing is a laboratory assay that quantifies insulin-like growth factor 1 in blood to assess growth hormone axis activity and support the diagnosis of endocrine disorders such as acromegaly and growth hormone deficiency. This technical guide explains the biological basis of IGF-1 measurement, acceptable sample types, validated analytical methods, interpretation considerations, and frequently asked questions for clinicians and laboratory professionals.

Technical Overview

Insulin-like growth factor 1 (IGF-1), historically referred to as somatomedin C, is a 70-amino-acid single-chain polypeptide with a molecular weight of approximately 7.6 kDa. It is structurally homologous to proinsulin and functions as the principal mediator of the anabolic and growth-promoting effects of growth hormone (GH). Although the liver is the dominant source of circulating IGF-1, the peptide is also produced locally in bone, muscle, adipose tissue, and other organs, where it exerts autocrine and paracrine actions.

Hepatic IGF-1 synthesis is stimulated by GH binding to hepatic GH receptors and activating the JAK2-STAT5 signaling pathway. In the systemic circulation, more than 99% of IGF-1 is bound to six high-affinity insulin-like growth factor binding proteins (IGFBP-1 through IGFBP-6), with IGFBP-3 and the acid-labile subunit (ALS) forming the dominant ternary complex. This binding markedly prolongs the circulating half-life of IGF-1 to 12 to 16 hours or longer, in contrast to the short, pulsatile secretion pattern of GH.

Because IGF-1 concentrations integrate GH secretory activity over time and exhibit minimal diurnal fluctuation, a single IGF-1 measurement provides a stable and diagnostically reliable reflection of mean GH output. This property makes IGF-1 the preferred first-line biochemical marker for screening and monitoring disorders of GH excess and deficiency.

Testing Samples

Serum (Preferred Sample Type)

Venous blood is collected into a plain tube or serum separator tube (SST), allowed to clot for 30 to 60 minutes at room temperature, and centrifuged to obtain serum. Serum is the matrix validated by the majority of commercial IGF-1 immunoassay platforms. A typical collection volume of 2 to 5 mL of whole blood yields sufficient serum for routine analysis and repeat testing.

Plasma

Plasma anticoagulated with EDTA or lithium heparin may be acceptable if the specific assay manufacturer has validated the matrix. Heparin can occasionally interfere with certain immunoassay chemistries, so laboratory-specific validation is essential before substituting plasma for serum.

Sample Preparation and Storage

• Fasting for 8 to 12 hours prior to collection is recommended, since insulin and nutritional status can influence IGF-1 and IGFBP concentrations.
• Avoid strenuous physical exercise and acute illness before sampling, as both conditions can alter GH-IGF axis dynamics.
• Record the patient age and sex on the request form because reference intervals are strongly age- and sex-dependent.
• Samples are stable at 2 to 8°C for up to 48 to 72 hours in most validated protocols.
• For longer storage, serum or plasma should be aliquoted and frozen at -20°C or preferably -70°C.
• Repeated freeze-thaw cycles must be avoided, as they can degrade binding proteins and compromise assay accuracy.

Testing Items

The core analyte in routine IGF-1 biochemical testing is total serum IGF-1, which encompasses both the free and binding-protein-associated fractions measured after release from IGFBPs during assay pretreatment. Additional related analytes may be ordered in combination to strengthen diagnostic interpretation.

• Total IGF-1: the primary marker for GH axis evaluation, screening for acromegaly, and monitoring of GH replacement or suppression therapy.
• Free or bioavailable IGF-1: measured in specialized settings to assess the unbound, biologically active fraction, primarily in research or complex endocrine cases.
• IGFBP-3: the principal carrier protein, often paired with IGF-1 to evaluate growth disorders in children and to improve diagnostic specificity.
• Dynamic GH testing: GH stimulation tests (such as insulin tolerance, arginine, or clonidine tests) and suppression tests (oral glucose tolerance test) complement IGF-1 results when confirmatory evidence is required.

Testing Methods

Chemiluminescence and Electrochemiluminescence Immunoassays

Automated chemiluminescent immunoassay (CLIA) and electrochemiluminescent immunoassay (ECLIA) platforms are the current mainstay of clinical IGF-1 testing. These sandwich-format assays use capture and detection antibodies directed against distinct IGF-1 epitopes and incorporate acidic buffers, detergents, or blocking agents to dissociate IGF-1 from IGFBPs and eliminate binding-protein interference. Automated platforms deliver short turnaround times, broad analytical ranges, and excellent intra-laboratory precision.

Enzyme-Linked Immunosorbent Assay (ELISA)

Microplate ELISA remains widely used in research laboratories and smaller clinical settings. ELISA kits require acid-ethanol extraction or ultracentrifugation pretreatment to liberate IGF-1 from the ternary complex before quantification. While cost-effective and flexible, manual ELISA demands rigorous technique and careful control of incubation conditions to limit inter-assay variability.

Legacy Radioimmunoassay and Immunoradiometric Methods

Historic radioimmunoassay (RIA) and immunoradiometric assay (IRMA) formats provided the foundation for IGF-1 measurement but have largely been replaced by non-isotopic automated methods due to radioactive handling requirements, longer incubation times, and limited throughput.

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

LC-MS/MS is an emerging reference method that quantifies IGF-1 with high analytical specificity and minimal antibody cross-reactivity. Following proteolytic digestion or immunoextraction, multiple reaction monitoring enables accurate quantification across the full pathophysiological range. Mass spectrometry plays a growing role in assay harmonization and in resolving discrepancies between immunoassay platforms.

Method Standardization and Quality Control

• Calibration is traceable to the WHO International Standard for IGF-1 (02/254), supporting comparability across laboratories and assay lots.
• Laboratories must establish age-specific and sex-specific reference intervals, as IGF-1 peaks during puberty and declines progressively with advancing age.
• Internal quality control materials at low, normal, and high concentrations should be run with each analytical batch.
• External quality assessment program participation is recommended to monitor inter-laboratory agreement and detect systematic bias.
• Lot-to-lot reagent verification is required to ensure consistent longitudinal results, particularly for therapy monitoring.

Applications

IGF-1 biochemical testing is indispensable across multiple clinical and research domains involving the growth hormone axis.

• Acromegaly and gigantism: elevated IGF-1, confirmed with an oral glucose GH suppression test, supports the diagnosis of GH excess, and serial IGF-1 measurements guide the response to transsphenoidal surgery, somatostatin analogs, dopamine agonists, pegvisomant, and radiotherapy.
• Growth hormone deficiency: low or below-age-expected IGF-1 raises suspicion of GH deficiency in children with short stature and in adults with suspected hypopituitarism, prompting confirmatory GH stimulation testing.
• Pediatric growth disorders: IGF-1 combined with IGFBP-3 assists in differentiating GH deficiency, GH insensitivity syndromes such as Laron syndrome, malnutrition, and constitutional growth delay.
• Therapeutic drug monitoring: IGF-1 titration targets optimize recombinant human GH replacement, maintaining efficacy while avoiding overtreatment.
• Pituitary disease follow-up: periodic IGF-1 surveillance detects recurrence of GH-secreting adenomas after treatment.
• Metabolic and oncology research: IGF-1 is investigated as a biomarker in diabetes, metabolic syndrome, aging, and cancer risk studies, given its roles in insulin sensitization, cell proliferation, and apoptosis regulation.

FAQ

Why is IGF-1 measured instead of a random growth hormone level? GH is secreted in pulses with dramatic minute-to-minute variation, so a random GH sample cannot distinguish normal from abnormal secretion. IGF-1 remains stable throughout the day and reflects integrated GH activity, making a single measurement diagnostically meaningful.

Is fasting required before IGF-1 testing? Fasting is generally recommended but not strictly mandatory, since IGF-1 fluctuates far less than GH. However, recent high-calorie intake, acute illness, or intense exercise may still shift results, and standardized morning fasting collection yields the most interpretable values.

Which factors can falsely alter IGF-1 results? Oral estrogen therapy lowers hepatic IGF-1 production, pregnancy and late adolescence raise it, and malnutrition, severe liver disease, poorly controlled diabetes, and hypothyroidism reduce it. Clinicians should interpret values within the full clinical context.

How are reference ranges applied? Laboratories use age-specific and sex-specific intervals because IGF-1 rises sharply during puberty, reaches a lifetime peak, then declines steadily in adulthood. A result normal for a 60-year-old may be clearly abnormal for a 20-year-old.

What is the typical turnaround time? Automated immunoassay platforms generally report IGF-1 results within 24 hours of sample receipt, while send-out mass spectrometry testing may require several days.

What is the difference between IGF-1 and IGFBP-3 testing? IGF-1 is the direct effector marker of GH action, whereas IGFBP-3 is its principal transport protein and is also GH-dependent. IGFBP-3 is less age-dependent in young children, so combining both analytes improves the evaluation of short stature in pediatric practice.